Kineta expands in Seattle; Biotech groups merge into the California Life Sciences Association;

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Talked to two of the founders at Denali, which just drew a $217M round for neurodegeneration R&D. More | Follow @JohnCFierce

> An expanding Kineta has taken a larger space in Seattle's South Lake Union area. The biotech tells the Puget Sound Business Journal that it has hired on 9 new researchers and has a new, $10 million contract with the NIH on boosting vaccine efficacy. Story

> BayBio and the California Healthcare Institute have completed their merger, bringing together some 750 members into the California Life Sciences Association. Sara Radcliffe is president and CEO of CLSA. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Philips quality improvement plan hit by recall at its troubled Cleveland facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Which global markets should drugmakers target? China, yes--but old European standbys, too. More from FiercePharma | Follow @EmilyWFierce

> Medtronic's vein closure device recalled in Europe, Asia right around time of its U.S. launch. More

> FDA clears BD insulin infusion pump designed with diabetes patient advocacy groups. Article

Pharma News

@FiercePharma: Paul Allen Just Got One Step Closer To Mapping The Human Brain. More from Forbes | Follow @FiercePharma

@EricPFierce: Will Sun's Shanghvi use his top dog standing to influence other Indian drugmakers to step up their game? Check out the feature from FierceBiotech | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Contrave controversy puts Orexigen, Takeda in unwelcome spotlight. Article | Follow @CarlyHFierce

> Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom. Article

> Takeda puts screws on Orexigen for $200M do-over after 'compromised' heart trial. Report

Pharma Manufacturing News

> Troubled Wockhardt recalls blood pressure med in U.S. Story

> Romark recalls pediatric diarrhea treatment Alina. News

> Sun and Ranbaxy marriage puts Sun founder Shanghvi in position to influence industry. Item

> Danaher, drawn by Pall's biopharma biz, will pay $13.8B for filtration specialist. Article

> Perrigo buys Patheon's softgel operations in Mexico. Report

Pharma Asia News

> Japan's MHLW sets Sovaldi price, hep C competition heats up. More

> Ranbaxy faces U.S. racketeering suit for blocking launch of Roche, Novartis generics. Story

> India's Lupin buys Brazil's Medquimica as part of M&A growth plan. Report

> Australia budget promises more digging on reimbursement, fees. Item

> Japan readies to sign new IP law it sees as win-win. Article

Vaccines News

> NewLink continues cancer vaccine Ph III trial with interim data under wraps. Story

> BiondVax rounds up $9.5M in IPO. Item

> Bavarian Nordic smallpox vaccine scores two late-stage trial wins. Article

> NIH-backed West Nile candidate enters PhI trials at Duke. Story

> Nima Farzan takes over as PaxVax CEO. Report

CRO News

> QPS cuts the ribbon on a new lab for early-stage R&D. News

> Theorem expands in Europe with new supplies facility. More

> Evotec brightens its outlook after $286M Sanofi deal. Report

> Patheon sells off its Mexican division for $34M. Item

> WuXi weighs going private with a deal on the table. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.